{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,21]],"date-time":"2023-10-21T05:59:12Z","timestamp":1697867952840},"reference-count":64,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2015,11,1]],"date-time":"2015-11-01T00:00:00Z","timestamp":1446336000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","progcardvascdis.com","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Progress in Cardiovascular Diseases"],"published-print":{"date-parts":[[2015,11]]},"DOI":"10.1016\/j.pcad.2015.09.001","type":"journal-article","created":{"date-parts":[[2015,9,5]],"date-time":"2015-09-05T02:46:01Z","timestamp":1441421161000},"page":"285-298","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Duration of Dual Anti-Platelet Therapy Post-Percutaneous Intervention: Is There A Correct Amount of Time?"],"prefix":"10.1016","volume":"58","author":[{"given":"Kirk N.","family":"Garratt","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.pcad.2015.09.001_bb0005","doi-asserted-by":"crossref","first-page":"e574","DOI":"10.1161\/CIR.0b013e31823ba622","article-title":"2011 ACCF\/AHA\/SCAI guideline for percutaneous coronary intervention: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions","volume":"124","author":"Levine","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.pcad.2015.09.001_bb0010","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1136\/bmj.308.6921.81","article-title":"Collaborative overview of randomized trials of antiplatelet therapy, I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients","volume":"308","year":"1994","journal-title":"Br Med J"},{"key":"10.1016\/j.pcad.2015.09.001_bb0015","doi-asserted-by":"crossref","first-page":"S247","DOI":"10.1378\/chest.108.4_Supplement.247S","article-title":"Aspirin and other plate let-active drugs: the relationship between dose, effectiveness, and side-effects","volume":"108","author":"Hirsh","year":"1995","journal-title":"Chest"},{"key":"10.1016\/j.pcad.2015.09.001_bb0020","series-title":"Ticlopidine, platelets and vascular disease","first-page":"99","article-title":"A systematic overview of randomized trials of antiplatelet agents for the prevention of stroke, myocardial infarction, and vascular death","author":"Gent","year":"1993"},{"key":"10.1016\/j.pcad.2015.09.001_bb0025","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/S0140-6736(96)09457-3","article-title":"A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee","volume":"348","author":"CAPRIE Steering Committee","year":"1996","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.pcad.2015.09.001_bb0030","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1067\/mhj.2002.121929","volume":"143","author":"Berger","year":"2002","journal-title":"Am Heart J"},{"key":"10.1016\/j.pcad.2015.09.001_bb0035","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1056\/NEJM199812033392303","article-title":"A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting","volume":"339","author":"Leon","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2015.09.001_bb0040","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1056\/NEJMoa010746","article-title":"Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST segment elevation","volume":"345","author":"CURE Investigators","year":"2001","journal-title":"N Engl J Med"},{"issue":"9281","key":"10.1016\/j.pcad.2015.09.001_bb0045","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/S0140-6736(01)05701-4","article-title":"Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study","volume":"358","author":"Mehta","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.pcad.2015.09.001_bb0050","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1001\/jama.288.19.2411","article-title":"Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial","volume":"288","author":"Steinhubl","year":"2002","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.pcad.2015.09.001_bb0055","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ijcard.2015.03.049","article-title":"Protease-activated receptor-1 antagonists in long-term antiplatelet therapy. Current state of evidence and future perspectives","volume":"185","author":"Moschonas","year":"2015","journal-title":"Int J Cardiol"},{"issue":"7","key":"10.1016\/j.pcad.2015.09.001_bb0060","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1161\/ATVBAHA.107.144220","article-title":"Vascular responses to drug eluting stents: importance of delayed healing","volume":"27","author":"Finn","year":"2007","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.pcad.2015.09.001_bb0065","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1161\/CIRCULATIONAHA.110.003210","article-title":"Stent thrombogenicity early in high-risk interventional settings is driven by stent design and deployment and protected by polymer-drug coatings","volume":"123","author":"Kolandaivelu","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.pcad.2015.09.001_bb0070","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/j.jacc.2008.12.055","article-title":"Predictors of coronary stent thrombosis: the Dutch Stent Thrombosis Registry","volume":"53","author":"Van Werkum","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2015.09.001_bb0075","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.ahj.2008.02.012","article-title":"Correlates of late and very late stent thrombosis of drug eluting stents","volume":"156","author":"Mishkel","year":"2008","journal-title":"Am Heart J"},{"key":"10.1016\/j.pcad.2015.09.001_bb0080","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.amjcard.2008.04.068","article-title":"A clinical risk score for prediction of stent thrombosis","volume":"102","author":"Baran","year":"2008","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.pcad.2015.09.001_bb0085","doi-asserted-by":"crossref","first-page":"949","DOI":"10.4244\/EIJV6I8A165","article-title":"A clinical risk score for the prediction of very late stent thrombosis in drug eluting stent patients","volume":"6","author":"Baran","year":"2011","journal-title":"EuroIntervention"},{"key":"10.1016\/j.pcad.2015.09.001_bb0090","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/j.jcin.2012.07.012","article-title":"Development and validation of a stent thrombosis risk score in patients with acute coronary syndromes","volume":"5","author":"Dangas","year":"2012","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.pcad.2015.09.001_bb0095","doi-asserted-by":"crossref","first-page":"3198","DOI":"10.1161\/CIRCULATIONAHA.108.826479","article-title":"Safety and efficacy of drug-eluting and bare metal stents: comprehensive meta-analysis of randomized trials and observational studies","volume":"119","author":"Kirtane","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.pcad.2015.09.001_bb0100","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1161\/CIRCINTERVENTIONS.108.846741","article-title":"Bleeding in patients undergoing percutaneous coronary intervention: the development of a clinical risk algorithm from the National Cardiovascular Data Registry","volume":"2","author":"Mehta","year":"2009","journal-title":"Circ Cardiovasc Interv"},{"key":"10.1016\/j.pcad.2015.09.001_bb0105","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1002\/ccd.23337","article-title":"Prognostic implications of early and long-term bleeding events in patients on one-year dual antiplatelet therapy following drug-eluting stent implantation","volume":"80","author":"Musumeci","year":"2012","journal-title":"Catheter Cardiovasc Interv"},{"key":"10.1016\/j.pcad.2015.09.001_bb0110","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1136\/heartjnl-2013-304564","article-title":"Prognostic implications of bleeding measured by Bleeding Academic Research Consortium (BARC) categorisation in patients undergoing primary percutaneous coronary intervention","volume":"100","author":"Matic","year":"2014","journal-title":"Heart"},{"key":"10.1016\/j.pcad.2015.09.001_bb0115","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1093\/eurheartj\/ehm194","article-title":"Development and validation of a prognostic risk score for major bleeding in patients undergoing percutaneous coronary intervention via the femoral approach","volume":"28","author":"Nikolsky","year":"2007","journal-title":"Eur Heart J"},{"issue":"5","key":"10.1016\/j.pcad.2015.09.001_bb0120","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCINTERVENTIONS.114.002106","article-title":"Incremental value of platelet reactivity over a risk score of clinical and procedural variables in predicting bleeding after percutaneous coronary intervention via the femoral approach: development and validation of a new bleeding risk score","volume":"8","author":"Mangiacapra","year":"2015","journal-title":"Circ Cardiovasc Interv"},{"issue":"11","key":"10.1016\/j.pcad.2015.09.001_bb0125","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1001\/jama.2011.290","article-title":"Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS Randomized Trial","volume":"305","author":"Price","year":"2011","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.pcad.2015.09.001_bb0130","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1016\/j.jacc.2012.02.026","volume":"59","author":"Trenk","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2015.09.001_bb0135","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/S0735-1097(99)00271-5","article-title":"Acute and nine-month clinical outcomes after \u201csuboptimal\u201d coronary stenting","volume":"34","author":"Cutlip","year":"1999","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2015.09.001_bb0140","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1161\/CIRCULATIONAHA.106.685313","article-title":"Clinical end points in coronary stent trials: a case for standardized definitions","volume":"115","author":"Cutlip","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.pcad.2015.09.001_bb0145","doi-asserted-by":"crossref","first-page":"2736","DOI":"10.1161\/CIRCULATIONAHA.110.009449","article-title":"Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium","volume":"123","author":"Mehran","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.pcad.2015.09.001_bb0150","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1056\/NEJMoa067722","article-title":"Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden","volume":"356","author":"Lagerqvist","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2015.09.001_bb0155","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1056\/NEJMoa0809902","article-title":"Long-term safety and efficacy of drug-eluting versus bare-metal stents in Sweden","volume":"360","author":"James","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2015.09.001_bb0160","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1002\/ccd.21618","article-title":"Usage patterns and 2-year outcomes with the TAXUS express stent: results of the US ARRIVE 1 registry","volume":"72","author":"Lasala","year":"2008","journal-title":"Catheter Cardiovasc Interv"},{"key":"10.1016\/j.pcad.2015.09.001_bb0165","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1161\/CIRCULATIONAHA.104.532242","article-title":"Safety of coronary sirolimus-eluting stents in daily clinical practice: one-year follow-up of the e-Cypher registry","volume":"113","author":"Urban","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.pcad.2015.09.001_bb0170","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1001\/jama.297.2.joc60179","article-title":"Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation","volume":"297","author":"Eisenstein","year":"2007","journal-title":"J Am Med Assoc"},{"issue":"25","key":"10.1016\/j.pcad.2015.09.001_bb0175","doi-asserted-by":"crossref","first-page":"3198","DOI":"10.1161\/CIRCULATIONAHA.108.826479","article-title":"Safety and efficacy of drug-eluting and bare metal stents: comprehensive meta-analysis of randomized trials and observational studies","volume":"119","author":"Kirtane","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.pcad.2015.09.001_bb0180","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1016\/j.jacc.2010.07.016","article-title":"Stent thrombosis","volume":"56","author":"Holmes","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2015.09.001_bb0185","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1016\/j.jcin.2009.10.001","article-title":"Safety and effectiveness of the Endeavor zotarolimus-eluting stent in real-world clinical practice","volume":"2","author":"Lotan","year":"2009","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.pcad.2015.09.001_bb0190","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/j.jcin.2012.02.014","article-title":"Contemporary incidence and predictors of stent thrombosis and other major adverse cardiac events in the year after XIENCE V implantation","volume":"5","author":"Naidu","year":"2012","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.pcad.2015.09.001_bb0195","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.4244\/EIJY15M01_07","article-title":"One-year outcomes in 1,010 unselected patients treated with the PROMUS Element everolimus-eluting stent: the multicentre PROMUS Element European Post-Approval Surveillance Study","volume":"10","author":"Thomas","year":"2015","journal-title":"EuroIntervention"},{"key":"10.1016\/j.pcad.2015.09.001_bb0200","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1093\/eurheartj\/ehu084","article-title":"Modifying effect of dual antiplatelet therapy on incidence of stent thrombosis according to implanted drug-eluting stent type","volume":"35","author":"Camenzind","year":"2014","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pcad.2015.09.001_bb0205","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.amjcard.2012.10.030","article-title":"Benefit of long-term dual anti-platelet therapy in patients treatedwith drug-eluting stents: from the NHLBI dynamic registry","volume":"111","author":"Mulukutla","year":"2013","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.pcad.2015.09.001_bb0210","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1056\/NEJMoa1409312","article-title":"Twelve or 30months of dual antiplatelet therapy after drug-eluting stent","volume":"371","author":"Mauri","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2015.09.001_bb0215","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1093\/eurheartj\/ehu523","article-title":"ISAR-SAFE: a randomized, double-blind, placebo-controlled trial of 6 vs. 12months of clopidogrel therapy after drug-eluting stenting","volume":"36","author":"Schulz-Sch\u00fcpke","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pcad.2015.09.001_bb0220","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/j.ahj.2010.07.038","volume":"160","author":"Mauri","year":"2010","journal-title":"Am Heart J"},{"key":"10.1016\/j.pcad.2015.09.001_bb0225","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1056\/NEJM199309023291001","article-title":"An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction","volume":"329","author":"The GUSTO Investigators","year":"1993","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.pcad.2015.09.001_bb0230","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.ahj.2011.11.002","article-title":"Rationale and design of the TAXUS Libert\u00e9 Post-Approval Study: examination of patients receiving the TAXUS Libert\u00e9 stent with concomitant prasugrel therapy in routine interventional cardiology practice","volume":"163","author":"Garratt","year":"2012","journal-title":"Am Heart J"},{"key":"10.1016\/j.pcad.2015.09.001_bb0235","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1161\/CIRCULATIONAHA.114.013570","article-title":"Prasugrel plus aspirin beyond 12months is associated with improved outcomes after TAXUS Libert\u00e9 paclitaxel-eluting stent placement","volume":"131","author":"Garratt","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.pcad.2015.09.001_bb0240","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/S0140-6736(14)62052-3","article-title":"Extended duration dual antiplatelet therapy and mortality: a systematic review and meta-analysis","volume":"385","author":"Elmariah","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.pcad.2015.09.001_bb0245","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1001\/jama.293.17.2126","article-title":"Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents","volume":"293","author":"Iakovou","year":"2005","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.pcad.2015.09.001_bb0250","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/j.jcin.2014.04.017","article-title":"Correlates and outcomes of late and very late drug-eluting stent thrombosis: results from DESERT (International Drug-Eluting Stent Event Registry of Thrombosis)","volume":"7","author":"Waksman","year":"2014","journal-title":"J Am Coll Cardiol Intv"},{"key":"10.1016\/j.pcad.2015.09.001_bb0255","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1161\/CIRCULATIONAHA.111.059022","article-title":"The Efficacy of Xience\/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) Randomized, Multicenter Study","volume":"125","author":"Gwon","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.pcad.2015.09.001_bb0260","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1016\/j.jacc.2012.06.043","article-title":"A new strategy for discontinuation of dual antiplatelet therapy: the RESET Trial (REal Safety and Efficacy of 3-month dual antiplatelet Therapy following Endeavor zotarolimus-eluting stent implantation)","volume":"60","author":"Kim","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2015.09.001_bb0265","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1093\/eurheartj\/ehs460","article-title":"Should duration of dual antiplatelet therapy depend on the type and\/or potency of implanted stent? A prespecified analysis from the PROlonging Dual antiplatelet treatment after Grading stent-induced Intimal hyperplasia studY (PRODIGY)","volume":"34","author":"Valgimigli","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pcad.2015.09.001_bb0270","first-page":"2510","article-title":"Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial","volume":"310","author":"Feres","year":"2013","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.pcad.2015.09.001_bb0275","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.jacc.2014.11.008","article-title":"6- versus 24-month dual antiplatelet therapy after implantation of drug-eluting stents in patients nonresistant to aspirin: the randomized, multicenter ITALIC trial","volume":"65","author":"Gilard","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2015.09.001_bb0280","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1016\/j.jacc.2014.09.008","article-title":"Second-generation drug-eluting stent implantation followed by 6- versus 12-month dual antiplatelet therapy: the SECURITY randomized clinical trial","volume":"64","author":"Colombo","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2015.09.001_bb0285","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.amjcard.2014.04.035","article-title":"Meta-analysis of randomized clinical trials comparing short-term versus long-term dual antiplatelet therapy following drug-eluting stents","volume":"114","author":"El-Hayek","year":"2014","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.pcad.2015.09.001_bb0290","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1002\/ccd.25520","article-title":"Shorter (\u22646months) versus longer (\u226512months) duration dual antiplatelet therapy after drug eluting stents: a meta-analysis of randomized clinical trials","volume":"85","author":"Pandit","year":"2015","journal-title":"Catheter Cardiovasc Interv"},{"key":"10.1016\/j.pcad.2015.09.001_bb0295","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/j.jacc.2014.06.1158","article-title":"Short versus long duration of DAPT after DES implantation: a meta-analysis","volume":"64","author":"Stefanini","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2015.09.001_bb0300","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1016\/j.jacc.2014.12.046","article-title":"Short- versus long-term dual antiplatelet therapy after drug-eluting stent implantation: an individual patient data pairwise and network meta-analysis","volume":"65","author":"Palmerini","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2015.09.001_bb0305","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1056\/NEJMoa1001266","article-title":"Duration of dual antiplatelet therapy after implantation of drug-eluting stents (REAL\/ZEST-LATE)","volume":"362","author":"Park","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2015.09.001_bb0310","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1016\/j.jacc.2015.01.039","article-title":"Duration of dual antiplatelet therapy after drug-eluting stent implantation: a systematic review and meta-analysis of randomized controlled trials","volume":"65","author":"Giustino","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2015.09.001_bb0315","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1016\/S0140-6736(14)60612-7","article-title":"Dual-antiplatelet treatment beyond 1year after drug-eluting stent implantation (ARCTIC-Interruption): a randomised trial","volume":"384","author":"Collet","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.pcad.2015.09.001_bb0320","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1161\/CIRCULATIONAHA.113.003303","article-title":"Optimal duration of dual antiplatelet therapy after drug-eluting stent implantation: a randomized, controlled trial","volume":"129","author":"Lee","year":"2014","journal-title":"Circulation"}],"container-title":["Progress in Cardiovascular Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0033062015000791?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0033062015000791?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,30]],"date-time":"2019-08-30T02:26:34Z","timestamp":1567131994000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0033062015000791"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11]]},"references-count":64,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015,11]]}},"alternative-id":["S0033062015000791"],"URL":"https:\/\/doi.org\/10.1016\/j.pcad.2015.09.001","relation":{},"ISSN":["0033-0620"],"issn-type":[{"value":"0033-0620","type":"print"}],"subject":[],"published":{"date-parts":[[2015,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Duration of Dual Anti-Platelet Therapy Post-Percutaneous Intervention: Is There A Correct Amount of Time?","name":"articletitle","label":"Article Title"},{"value":"Progress in Cardiovascular Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pcad.2015.09.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}